Physiology- or Imaging-Guided Strategies for Intermediate Coronary Stenosis.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 Jan 2024
Historique:
medline: 4 1 2024
pubmed: 4 1 2024
entrez: 3 1 2024
Statut: epublish

Résumé

Treatment strategies for intermediate coronary lesions guided by fractional flow reserve (FFR) and intravascular ultrasonography (IVUS) have shown comparable outcomes. Identifying low-risk deferred vessels to ensure the safe deferral of percutaneous coronary intervention (PCI) and high-risk revascularized vessels that necessitate thorough follow-up can help determine optimal treatment strategies. To investigate outcomes according to treatment types and FFR and IVUS parameters after FFR- or IVUS-guided treatment. This cohort study included patients with intermediate coronary stenosis from the Fractional Flow Reserve and Intravascular Ultrasound-Guided Intervention Strategy for Clinical Outcomes in Patients With Intermediate Stenosis (FLAVOUR) trial, an investigator-initiated, prospective, open-label, multicenter randomized clinical trial that assigned patients into an IVUS-guided strategy (which recommended PCI for minimum lumen area [MLA] ≤3 mm2 or 3 mm2 to 4 mm2 with plaque burden [PB] ≥70%) or an FFR-guided strategy (which recommended PCI for FFR ≤0.80). Data were analyzed from November to December 2022. FFR or IVUS parameters within the deferred and revascularized vessels. The primary outcome was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction, and revascularization at 2 years. A total of 1619 patients (mean [SD] age, 65.1 [9.6] years; 1137 [70.2%] male) with 1753 vessels were included in analysis. In 950 vessels for which revascularization was deferred, incidence of TVF was comparable between IVUS and FFR groups (3.8% vs 4.1%; P = .72). Vessels with FFR greater than 0.92 in the FFR group and MLA greater than 4.5 mm2 or PB of 58% or less in the IVUS group were identified as low-risk deferred vessels, with a decreased risk of TVF (hazard ratio [HR], 0.25 [95% CI, 0.09-0.71]; P = .009). In 803 revascularized vessels, the incidence of TVF was comparable between IVUS and FFR groups (3.6% vs 3.7%; P = .95), which was similar in the revascularized vessels undergoing PCI optimization (4.2% vs 2.5%; P = .31). Vessels with post-PCI FFR of 0.80 or less in the FFR group or minimum stent area of 6.0 mm2 or less or with PB at stent edge greater than 58% in the IVUS group had an increased risk for TVF (HR, 7.20 [95% CI, 3.20-16.21]; P < .001). In this cohort study of patients with intermediate coronary stenosis, FFR- and IVUS-guided strategies showed comparable outcomes in both deferred and revascularized vessels. Binary FFR and IVUS parameters could further define low-risk deferred vessels and high-risk revascularized vessels.

Identifiants

pubmed: 38170524
pii: 2813462
doi: 10.1001/jamanetworkopen.2023.50036
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2350036

Auteurs

Seokhun Yang (S)

Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.

Jeehoon Kang (J)

Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.

Doyeon Hwang (D)

Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.

Jinlong Zhang (J)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.

Jun Jiang (J)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.

Xinyang Hu (X)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.

Joo-Yong Hahn (JY)

Samsung Medical Center, Seoul, Republic of Korea.

Chang-Wook Nam (CW)

Keimyung University Dongsan Medical Center, Daegu, Republic of Korea.

Joon-Hyung Doh (JH)

Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.

Bong-Ki Lee (BK)

Kangwon National University Hospital, Chuncheon, Gangwon-Do, Republic of Korea.

Weon Kim (W)

Kyung Hee University Hospital, Seoul, Republic of Korea.

Jinyu Huang (J)

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Fan Jiang (F)

Hangzhou Normal University Affiliated Hospital, Hangzhou, China.

Hao Zhou (H)

The 1st Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Peng Chen (P)

The 2nd Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Lijiang Tang (L)

Zhejiang Hospital, Hangzhou, China.

Wenbing Jiang (W)

The Third Clinical Institute Affiliated To Wenzhou Medical University, Wenzhou, China.

Xiaomin Chen (X)

Ningbo First Hospital, Ningbo, China.

Wenming He (W)

The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.

Sung Gyun Ahn (SG)

Wonju Severance Christian Hospital, Wonju, Gangwon-Do, Republic of Korea.

Myeong-Ho Yoon (MH)

Ajou University Hospital, Suwon, Republic of Korea.

Ung Kim (U)

Yeungnam University Medical Center, Daegu, Republic of Korea.

Joo Myung Lee (JM)

Samsung Medical Center, Seoul, Republic of Korea.

You-Jeong Ki (YJ)

Uijeongbu Eulji Medical Center, Uijeongbu, Gyeonggi-Do, Republic of Korea.

Eun-Seok Shin (ES)

Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.

Hyo-Soo Kim (HS)

Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.

Seung-Jea Tahk (SJ)

Ajou University Hospital, Suwon, Republic of Korea.

Jian'an Wang (J)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.

Bon-Kwon Koo (BK)

Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.

Classifications MeSH